Afuresertib is a potent pan-AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in the pivotal-stage clinical development for anti-cancer treatment globally.

Afuresertib has demonstrated several advantages compared to other AKT inhibitors, including higher efficacy, better potency, more significant tumor inhibition exposure and a better safety profile, based on public data. Laekna continues to develop along with Novartis early phase clinical development, such as PROC, and expand the oncology indications by selecting additional combination therapies in different drug-resistant solid tumors that beyond Novartis early clinical development, such as HR+/HER2-breast cancer, mCRPC, TNBC, PD-1-resistant cervical cancer and endometrial cancer, etc.

In serval clinical trials, the combination of Afuresertib with other therapeutics also exhibits favorable efficacy results.

LAE001 is an androgen synthesis inhibitor that inhibits both CYP17A1 and CYP11B2. Laekna in-licensed LAE001 from Novartis in 2017. According to Frost & Sullivan, LAE001 is the only dual CYP17A1/CYP11B2 inhibitor in clinical trials for the treatment of prostate cancer globally. As a dual CYP17A1/CYP11B2 inhibitor, LAE001 can block both androgen and aldosterone synthesis and potentially be administrated without prednisone, the short-term high dose or longterm exposure of which can lead to a variety of adverse events.

Laekna completed the Phase I clinical trial and initiated the Phase II clinical trial of a Phase I/II study in China to assess the safety and efficacy of LAE001 as a monotherapy at recommended Phase II dose (RP2D) in mCRPC.